Bcl-2结合组件3(BBC3)作为乳腺癌精准生物标志物
本文综述了BBC3(PUMA)作为乳腺癌血清生物标志物的分子调控、分析前变量、定量平台性能及临床验证数据,并提供了质量控制、参考区间建立和自动化整合的操作建议,旨在为实验室和临床提供标准化方案。
要点
- BBC3是促凋亡BH3-only蛋白,其表达失调与肿瘤诊断相关。
- 需评估ELISA、qRT-PCR、digital PCR和质谱等平台的分析性能。
- 综述提供了BBC3检测的质量控制与参考区间建立建议。
核心结论
- BBC3有潜力作为乳腺癌早期检测、监测和预后的血清生物标志物,但需按临床化学标准严格评估。
研究设计与样本
- 综述类文章,检索并汇总了BBC3分子调控、分析前变量、定量平台性能及多个队列的临床验证数据。
主要发现
- BBC3在肿瘤组织和循环中表达失调,涉及诊断潜力。
- 综述评估了ELISA、qRT-PCR、digital PCR和质谱等平台的检测限、定量、精密度、准确性、线性和特异性。
- 汇总了多个队列中BBC3的灵敏度、特异性、ROC-AUC、预测值及与肿瘤分期和治疗反应的相关性。
- 与CA 15-3、CEA、cfDNA和miRNA panel等标志物进行了比较分析。
关键数值与推荐
- 综述汇总了BBC3定量平台的分析性能指标(检测限、定量、精密度、准确性、线性和特异性)及临床验证数据(灵敏度、特异性、ROC-AUC、预测值)。
- 提供了质量控制程序、参考区间建立、通量优化和自动化平台整合的操作建议。
临床怎么用
- 为实验室科学家和临床医生提供标准化方案,以在常规实践中采用血清BBC3检测,增强乳腺癌早期检测、治疗监测和个体化管理。
局限性
- 血清BBC3定量的分析性能、分析前要求和临床效用尚未按临床化学标准严格评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast cancer is the most prevalent carcinoma in women globally, and the identification of sensitive and specific serum biomarkers is important for its early detection, monitoring, and prognosis. Bcl-2 binding component 3 (BBC3), also known as p53 upregulated modulator of apoptosis (PUMA), is a proapoptotic- BH3-only protein whose dysregulated expression in tumor tissues and circulation implicates it as a potential diagnostic biomarker. However, the analytical performance, preanalytical- requirements, and clinical utility of serum BBC3 quantification have not been rigorously assessed according to clinical chemistry- standards. This review examines the molecular regulation and structural features of BBC3 relevant to analytical assay design, key preanalytical- variables, including specimen collection, processing intervals, and storage conditions, and evaluates quantitative platforms, such as enzyme-linked immunosorbent assay (ELISA), quantitative reverse-transcription polymerase chain reaction (qRT-PCR), digital polymerase chain reaction (digital PCR), and mass spectrometry (MS)- in terms of limits of detection, quantification, precision, accuracy, linearity, and specificity. We reviewed clinical validation data from multiple cohorts and reported the sensitivity, specificity, receiver operating characteristic area under the curve (ROC-AUC), predictive values, and correlations with tumor stage and treatment response. Comparative analyses with established markers, including cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA), cell-free DNA (cfDNA), and microRNA (miRNA) panels are presented. Additionally, operational recommendations are provided for quality control procedures, establishment of reference intervals, throughput optimization, and integration with automated platforms. The primary contribution of this study lies in its comprehensive review of molecular insights, assay validation, and clinical application strategies specifically designed to meet the requirements of clinical laboratories. This study aimed to provide laboratory scientists and clinicians with a standardized protocol for adopting serum BBC3 measurements in routine practice, thereby enhancing early detection, therapeutic monitoring, and individualized patient management in patients with breast cancer.
引用
- Fuloria NK, Fuloria S, Subramaniyan V, et al. Bcl-2 binding component 3 (BBC3) as a precision biomarker in breast cancer. Clin Chim Acta. 2025. PMID: 40846167. doi:10.1016/j.cca.2025.120564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。